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Background: Tenofovir alafenamide (TAF) is a novel tenofovir
prodrug with improved renal and bone safety compared with TDF-
containing regimens. We report the 48 week safety and efﬁcacy of
a once-daily single tablet regimen of elvitegravir 150 mg (E), cobicistat
150 mg (C), emtricitabine 200 mg (F), and TAF 10 mg (E/C/F/TAF) in
HIV-1-infected patients with mild to moderate renal impairment.
Methods: We enrolled virologically suppressed HIV-1-infected
subjects with estimated creatinine clearance (CrCl) 30–69 mL/min in
a single-arm, open-label study to switch regimens to E/C/F/TAF.
The primary endpoint was the change from baseline in glomerular
ﬁltration rate estimated using various formulae. This study is
registered with ClinicalTrials.gov, number NCT01818596.
Findings: We enrolled and treated 242 patients with mean age 58
years, 18% Black, 39% hypertension, 14% diabetes. Through week
48, no signiﬁcant change in estimated CrCl was observed. Two
patients (0.8%) discontinued study drug for decreased creatinine
clearance, neither had evidence of renal tubulopathy and both had
uncontrolled hypertension. Subjects had signiﬁcant improvements in
proteinuria, albuminuria, and tubular proteinuria (P , 0.001 for all).
Hip and spine bone mineral density signiﬁcantly increased from
baseline to week 48 (mean percent change +1.47 and +2.29,
respectively, P , 0.05). Ninety-two percent (222 patients) main-
tained HIV-1 RNA ,50 copies per milliliter at week 48.
Interpretation: Switch to E/C/F/TAF was associated with mini-
mal change in GFR. Proteinuria, albuminuria and bone mineral
density signiﬁcantly improved. These data support the efﬁcacy and
safety of once daily E/C/F/TAF in HIV+ patients with mild or
moderate renal impairment without dose adjustment.
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INTRODUCTION
Renal disease is an important contributor to morbidity and
mortality in HIV-infected patients.1–4 The prevalence of chronic
kidney disease (CKD) among people with HIV-1 infection in the
United States is 16% and is expected to rise as this population
ages.5–8 The use of the currently approved nucleo(s)tides is
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cautioned in patients with increased risk of CKD and cardio-
vascular disease, given the potential for tenofovir disoproxil
fumarate (TDF) nephrotoxicity and concern for cardiovascular
risk associated with abacavir (ABC). For patients who cannot
take either TDF or ABC, guidelines consider the use of nucleos
(t)ide-sparing regimens as optional because of reduced virologic
activity. Simple HIV regimens with proven efﬁcacy that do not
increase risk of prevalent comorbidities, such as bone-related
comorbidity, decreased renal function, and cardiovascular risk,
are needed for improved adherence and patient outcomes.
Tenofovir alafenamide (TAF) is a novel tenofovir (TFV)
prodrug with pharmacokinetic (PK) properties distinct from
TDF. The renal and bone toxicities seen with 300 mg TDF are
associated with high circulating plasma levels of TFV,9–13 and
TAF has 90% lower plasma TFV than TDF in the TAF-
containing formulations currently in development. Because of
TAF’s reduced dose and a longer plasma half-life, plasma
exposure of TFV is 90% lower with TAF than with TDF, which
is hypothesized to reduce the risk of renal and bone toxicities.
Findings from 2 randomized, double-blind phase 3 trials
of TAF vs TDF, both coformulated with elvitegravir, cobicistat,
and emtricitabine (FTC), demonstrated noninferior efﬁcacy of
TAF vs TDF, with a signiﬁcantly reduced effect of TAF
compared with TDF on estimated glomerular ﬁltration rate
(eGFR), proteinuria, albuminuria, and bone mineral density
(BMD).14 To assess whether E/C/F/TAF is safe and reduces the
renal and bone effects associated with TDF-containing regi-
mens in patients with mild to moderate renal impairment,
a single-arm, open-label phase 3 clinical trial was conducted,
with a protocol-speciﬁed focus on renal and bone safety.
METHODS
Study Design and Patients
GS-US-292-0112 is a single-arm, open-label phase 3 study
performed at 70 outpatient centers in the United States, Thailand,
United Kingdom, Australia, Spain, France, Dominican Republic,
Mexico, and the Netherlands. The study was performed in
accordance with the Declaration of Helsinki and approved by
central or site-speciﬁc review boards or ethics committees. Each
patient gave written informed consent. HIV-1-infected adults
(aged $18 years) were enrolled in cohort 1 (switch) if they had
no known history of resistance to elvitegravir, TDF, or FTC;
plasma HIV-1 RNA concentrations at undetectable levels for at
least 6 months preceding the screening visit, and had HIV-1
RNA ,50 copies per milliliter at screening, eGFRCG (CG,
Cockroft-Gault) 30–69 mL/min, CD4+ cell count of $50 cells
per microliter, and stable renal function (a serum creatinine at
least once within 3 months of screening that is not $25%
different from the serum creatinine at screening), and cause of
underlying CKD stable without change in medical management
for 3 months before baseline. Patients with positive hepatitis B
surface antigen or hepatitis C antibody or a new AIDS-deﬁning
illness within 30 days of screening were excluded. Six additional
patients who had no previous antiretroviral treatment were
included in cohort 2 [antiretroviral (ARV) naive], but because
of the small sample size, these data are summarized separately
(see Appendix, Supplemental Digital Content, http://links.lww.
com/QAI/A772).
Procedures
Eligible patients received coformulated 150 mg elvite-
gravir, 150 mg cobicistat, 200 mg FTC, and 10 mg TAF (E/C/
F/TAF) once daily administered with food. Post-baseline
study visits occurred at weeks 1, 2, 4, 8, 12, 16, 24, 36, and
48, after which patients continued treatment with visits every
12 weeks until week 96.
Safety was assessed by physical examinations, labora-
tory tests, 12-lead electrocardiogram, and recording of
adverse events. The PK of the components of E/C/F/TAF
were evaluated through an intensive PK substudy performed
on a subset of patients at sites with capability at week 4 or 8,
which included plasma sampling for elvitegravir, cobcicistat,
FTC, TAF, and TFV. Bioanalytical analyses of drug concen-
trations in plasma were done by QPS (Newark, DE).
Laboratory tests included hematological analysis, serum
chemistry tests, fasting lipid parameters, CD4+ cell counts; and
measures of renal function [eGFR, urine protein to creatinine
ratio (UPCR), urine albumin to creatinine ratio (UACR),
retinol-binding protein to creatinine ratio, b2-microglobulin to
creatinine ratio, fractional excretion of uric acid, and fractional
excretion of phosphate; Covance Laboratories, Indianapolis,
IN]; HIV-1 RNA concentration (COBAS TaqMan HIV-1 Test,
v2.0; Roche Diagnostics, Rotkreuz, Switzerland); and, in
a convenience sample at sites with capability, measured GFR
(mGFR) as assessed by iohexol clearance.
Virologic failure was deﬁned as having HIV-1 RNA
$50 copies per milliliter, conﬁrmatory on a second sample
drawn within 3–6 weeks. Conﬁrmatory samples with HIV-1
RNA $400 copies per milliliter were sent for HIV-1
genotype/phenotype analysis (PhenoSense GT for Protease
and Reverse Transcriptase genes and GenSeq Integrase and
Phenosense Integrase for the Integrase gene; Monogram
Biosciences, South San Francisco, CA).
In all patients, dual energy x-ray absorptiometry scans
of the lumbar spine and hip were done at baseline, week 24,
and week 48 to measure percent change in BMD. The scans
were processed by BioClinica (Newton, PA).
The primary endpoint was the change from baseline at
week 24 in eGFRCG, eGFRCKD-EPI-CysC based on Cystatin C,
and eGFRCKD-EPI-creat based on serum creatinine.
15 The
secondary endpoints included change from baseline at weeks
48 and 96 in eGFR estimations, mGFR, change from baseline
in renal and bone biomarkers, and hip and spine BMDs, at
weeks 24, 48, and 96, the incidence of adverse events and
graded laboratory abnormalities, and the proportion of patients
maintaining virologic control at weeks 24, 48, and 96 (HIV-1
RNA ,50 copies per milliliter, snapshot analysis algorithm).
The preliminary results were reviewed by an indepen-
dent data monitoring committee when 50 patients had
completed week 12. The primary endpoint analysis was done
after all enrolled patients had completed their week 24 study
visit or had prematurely discontinued study drug.
Statistical Analyses
For the primary endpoint (changes from baseline in
eGFRCG, eGFRCKD2EPI-cysC, and eGFRCKD-EPI-creat) and for
other secondary renal, bone, and metabolic endpoints,
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changes from baseline were summarized by visit using
descriptive statistics and the median change from baseline
was analyzed by 2-sided Wilcoxon signed rank test. In
addition, change in mGFR was assessed using a parametric
analysis of variance model, and comparisons of geometric
least square mean ratios between week 24 and baseline and
week 2, 4, or 8 and baseline, with 90% conﬁdence intervals
(CIs), were used with a prespeciﬁed lack of alteration
boundary of 80%–125%. Subgroup analyses were conducted
for all the above renal, bone, and metabolic endpoints for
patients taking TDF-containing regimen before switch and for
patients with baseline eGFRCG ,50 mL/min.
Adverse events were coded with the Medical Dictio-
nary for Regulatory Activities (version 17.0).
Number and percentage of patients with virologic
success (achieved HIV-1 RNA ,50 copies per milliliter),
virologic failure, and reasons for no virologic data at week 48
as deﬁned by the U.S. Food and Drug Administration snapshot
algorithm were summarized. The 95% CIs for virologic success
rate were constructed using the exact method.
This study was conducted according to the protocol
without signiﬁcant deviations and is registered with
ClinicalTrials.gov, number NCT01818596.
RESULTS
Study Population
Two hundred forty-two patients with stable eGFRCG
30–69 mL/min (including 80 patients with baseline eGFRCG
,50 mL/min) were enrolled and switched from baseline
antiretroviral treatment regimens to receive E/C/F/TAF. The
median age was 58 years (range = 24–82 years), including 63
patients $65 year; 21% of patients were female, 18% of
patients identiﬁed themselves as Black, and median CD4 cell
count was 632 cells per microliter (Table 1). The median
eGFRCG at baseline was 56 mL/min, 42% of patients had
signiﬁcant proteinuria (UPCR . 200 mg/g), 49% had
signiﬁcant albuminuria (UACR $30 mg/g), 39% had hyper-
tension, and 14% were diabetic. ARV regimens before switch
were variable, with 65% taking a TDF-containing regimen,
22% taking an ABC-containing regimen, and 5% taking
a nucleos(t)ide-free regimen (see Figure S1, Supplemental
Digital Content, http://links.lww.com/QAI/A772). Median
(Q1, Q3) study drug exposure was 48.1 (43.1, 60.1) weeks.
Renal Safety
Through 48 weeks, no clinically appreciable change
from baseline in estimated creatinine clearance was observed,
with direction and magnitude varying by ﬁltration marker and
equation. Results were similar for patients whether baseline
eGFR was ,50 or $50 mL/min or whether they switched
from a TDF-based regimen (Table 2).
In the iohexol substudy (n = 32), actual GFR was not
affected over 24 weeks of treatment (see Figure S2a and 2b,
Supplemental Digital Content, http://links.lww.com/QAI/A772).
The geometric mean ratio (90% CI) between week 24 and
baseline was 103% (97%, 109%). No difference in mGFR
between week 24 and baseline was observed between patients
with baseline eGFRCG ,50 vs $50 mL/min or between those
taking TDF vs non–TDF-containing regimens before switching
to E/C/F/TAF.
Signiﬁcant improvements in total proteinuria, albumin-
uria, and tubular proteinuria (urine retinol-binding protein/
creatinine ratio and b2-microglobulin/creatinine ratio) were
observed (Fig. 1A). Improvements in renal parameters were
particularly marked in patients switching to E/C/F/TAF from
a TDF-containing regimen, whereas renal function in patients
switching from non-TDF regimens did not have signiﬁcant
changes. The prevalence of signiﬁcant proteinuria (UPCR .
200 mg/g) and albuminuria (UACR $ 30 mg/g) decreased
from 42% to 11% and from 49% to 21%, respectively (Figs.
1B, C). These changes occurred at week 1 and remained
through 48 weeks. Signiﬁcant improvements in other meas-
ures of renal tubular function, including fractional excretion
of uric acid levels [median (Q1, Q3) change from baseline
to week 48, 21.5 (23.6, 0.0); P , 0.001], were observed,
whereas there was no signiﬁcant change in fractional
excretion of phosphate [median (Q1, Q3) change from
baseline to week 48, 1.1 (24.1, 6.1), P = 0.07] or serum
phosphorus [median (Q1, Q3) change from baseline to week
48, 0.0 (20.4, 0.4); P = 0.50].
Eighty patients with baseline GFR,50 mL/min switched
to E/C/F/TAF. These patients were slightly older and had
a higher proportion of subjects with hypertension (see Table S1,
TABLE 1. Baseline Characteristics
Baseline eGFR
,50 mL/min,
n = 80
‡50 mL/min,
n = 162
Total,
N = 242
Median age, yr (range) 59 (31–82) 58 (24–76) 58 (24–82)
Age $ 65 yrs, n (%) 25 (31) 38 (23) 63 (26)
Female, n (%) 21 (26) 29 (18) 50 (21)
Black or African descent, % 18 19 18
HIV-1 RNA ,50 copies
per milliliter, %
98 98 98
Median CD4 count, cells
per microliter
622 635 632
Pre-switch TDF use, % 58 69 65
Hypertension, % 50 34 39
Diabetes, % 15 13 14
Median eGFRCG, mL/min 43 60 56
Median eGFRCKD-EPI, creatinine,
mL$min21$1.73 m22*
45 58 54
Median eGFRCKD-EPI, cystatin C,
mL$min21$1.73 m22†
57 77 70
Dipstick proteinuria grade
1 or 2, %‡
44 27 33
Signiﬁcant proteinuria, %§ 56 35 42
Signiﬁcant albuminuria, %¶ 64 42 49
CG, Cockroft-Gault.
*Chronic Kidney Disease Epidemiology Collaboration equation for eGFR using
serum creatinine (eGFRCKD-EPI, creatinine).
†CKD-EPI equation for eGFR using cystatin C (eGFRCKD-EPI, cystatin C).
‡Grade 1 (1+ on dipstick), grade 2 (2–3+ on dipstick); none had grade 3 or 4.
§UPCR . 200 mg/g.
¶UACR, ie, microalbuminuria $ 30 mg/g.
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As noted above, these patients had no signiﬁcant change from
baseline estimated creatinine clearance by any measure, and
other measures of renal function (proteinuria, albuminuria, and
tubular proteinuria) improved signiﬁcantly from baseline to
week 48. An exploratory analysis of patients with the lowest
(bottom 5%) eGFRCG and highest (top 5%) tubular proteinuria
demonstrated improvements for all measures (data not shown).
TABLE 2. Estimated GFR: Change From Baseline to Weeks 24 and 48
Median Change
(Q1, Q3) (mL/min)* Total, N = 242
,50 mL/min,
n = 80
‡50 mL/min,
n = 162
TDF Containing,
n = 158
Non-TDF Containing,
n = 84
Change at week 24
eGFRCG 20.4 (24.8, 4.5) +1.2 (23.9, 5.6) 20.9 (24.9, 3.6) +0.6 (24.5, 5.5) 20.9 (24.8, 2.4)
eGFRCKD-EPIsCr 21.8 (26.1, 4.9) +0.3 (24.1, 7.2) 22.2 (28.1, 3.7) 20.5 (27.1, 6.9) 22.3 (25.7, 2.2)
eGFRCKD-EPIcysC +3.8 (24.8, 11.2) +3.8 (24.8, 12.2) +3.8 (23.8, 10.7) +4.8 (23.0, 13.4) +1.5 (25.9, 8.9)
Change at week 48
eGFRCG 20.6 (25.4, 5.4) +0.6 (23.4, 6.9) 21.4 (26.3, 4.0) +0.2 (25.8, 6.3) 21.8 (24.5, 4.0)
eGFRCKD-EPIsCr 21.8 (27.9, 4.1) +1.4 (25.3, 6.1) 23.1 (28.9, 2.7) 21.5 (28.8, 6.0) 22.7 (25.8, 3.4)
eGFRCKD-EPIcysC +1.6 (27.4, 11.9) +1.1 (25.3, 11.3) +1.8 (28.9, 12.2) +2.7 (26.2, 14.1) 21.4 (28.5, 5.2)
*GFR estimated by Cockcroft–Gault, CKD-EPI serum creatinine, and CKD-EPI cystatin C.
FIGURE 1. A, Proteinuria: change from baseline to week 48. B, Significant proteinuria: baseline to week 48. C, Significant
albuminuria: baseline to week 48.
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Bone Mineral Density
BMD signiﬁcantly increased after switch to E/C/F/
TAF for patients on a TDF-containing regimen pre-switch
and remained stable after switch to E/C/F/TAF for patients
on non–TDF-containing regimen pre-switch. Mean percent
changes from baseline to week 48 in hip and spine
BMDs signiﬁcantly increased (+1.47% and +2.29%,
respectively), and more patients had signiﬁcant ($3%)
gains in hip or spine BMD than those who had signiﬁcant
loss (Figs. 2A, B).
Metabolic Changes
Fasting lipid levels decreased in patients who used non–
TDF-containing regimens before switching to E/C/F/TAF,
whereas levels increased in those using TDF-containing regi-
mens before switching to E/C/F/TAF (see Figure S3, Supple-
mental Digital Content, http://links.lww.com/QAI/A772).
However, there was no signiﬁcant difference in the total:high-
density lipoprotein (HDL) cholesterol ratio between those
receiving either TDF or non-TDF regimen before switch
because there were concordant changes for both the total
cholesterol and the HDL cholesterol fraction.
Adverse Events
E/C/F/TAF was well tolerated, with most adverse events
reported as mild or moderate in severity (see Table S2a,
Supplemental Digital Content, http://links.lww.com/QAI/A772).
Adverse events leading to study drug discontinuation were
uncommon, occurring in 3% of patients (n = 8). Two patients
(0.8%) discontinued study drug for decreased GFR by eGFRCG
and eGFRCKD-EPI, cystatin C. One patient (baseline eGFRCG = 49
mL/min) who had uncontrolled hypertension, an episode of
vomiting and dehydration, concomitant ramipril and valsartan,
and discontinued study drug after 3 months of therapy was
assessed by the investigator to have worsening renal insufﬁ-
ciency possibly related to the study drug. This patient had
signiﬁcant improvement in UPCR (1609–178 mg/g) and no
glycosuria. Another patient (baseline eGFRCG = 36 mL/min) was
considered to have progression of hypertension-related CKD
unrelated to the study drug. Neither of these subjects, or any
other study participant, had laboratory evidence of proximal renal
tubulopathy or Fanconi syndrome. There were 6 fractures, all
related to mechanical trauma and considered by the investigator
to be unrelated to the study drugs. The most common adverse
events were 11% diarrhea, 9% upper respiratory infection, 9%
arthralgia, 8% bronchitis, 8% osteopenia, 8% nausea, 7%
FIGURE 2. A, BMD: mean change
from baseline to week 48. B, Pro-
portions of patients with BMD changes.
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headache, 7% pain in extremity, 7% back pain, 6% dizziness, 6%
fatigue, 6% renal cyst, and 6% cough. Adverse events, grades,
and frequencies were similar in patients with baseline eGFR,50
vs $50 mL/min (see Table S2b, Supplemental Digital Content,
http://links.lww.com/QAI/A772). Because FTC was adminis-
tered at 200 mg daily, a comparison of FTC adverse drug
reactions was performed by baseline eGFRCG, and no signiﬁcant
difference between groups was observed (see Table S2c,
Supplemental Digital Content, http://links.lww.com/QAI/A772).
Pharmacokinetics
Plasma PK parameters of the components of E/C/F/TAF
in a subset of patients who participated in the intensive PK
substudy (n = 30) are presented in Table 3. The elvitegravir
(EVG) and cobicistat (COBI) PK parameters were in the range
of historical data after administration of E/C/F/TAF in HIV-
infected patients without renal impairment.16 EVG and COBI
exposure were comparable across eGFR groups of eGFRCG
,50 or $50 mL/min, consistent with the nonrenal elimination
pathway of these agents. As expected, because of FTC being
primarily renally eliminated, FTC PK was higher in patients in
this study vs historical E/C/F/TAF data in nonrenally impaired
patients. FTC exposure was higher in patients with eGFR ,50
vs $50 mL/min, consistent with the FTC PK parameters
reported for EMTRIVA in patients with mild or moderate renal
impairment.17 The TAF PK parameters were consistent with
historical data in nonrenally impaired patients. Additionally,
the TAF metabolite TFV, which is primarily renally elimi-
nated, was higher in patients in this study vs historical TAF
data in nonrenally impaired patients but was well below the
TFV exposures from TDF-containing regimens.18
Efficacy
At week 48, 222 patients (92%) maintained an HIV-1
RNA ,50 copies per milliliter, 17 patients (7%) did not have
virologic data available, and 3 patients (1%) were considered
to have virologic failure. Of these 3 patients, one patient had
HIV-1 RNA ,50 copies per milliliter on E/C/F/TAF before
switching to a new regimen, the second patient with HIV-1
RNA ,400 copies per milliliter on E/C/F/TAF demonstrated
nucleoside reverse transcriptase inhibitor and protease inhib-
itor resistance identical to a pre-study historical genotype, and
a third patient took additional ARVs (rilpivirine/FTC/TDF)
through day 67 (protocol violation) but was maintained on
E/C/F/TAF alone with HIV-1 RNA ,50 copies per milliliter
after that was noted through week 48. The mean increase
from baseline in CD4 cell counts through week 48 (observed
data) was +13 (SD = 170.1) cells per cubic millimeter.
DISCUSSION
Through 48 weeks, patients with mild to moderate renal
impairment (eGFR = 30–69 mL/min) who switched to TAF (E/
C/F/TAF) had no appreciable change in estimated or actual
GFR, whereas proteinuria, albuminuria, proximal renal tubular
function, and BMD signiﬁcantly improved. Of particular note,
the subset of patients with eGFR ,50 mL/min, who currently
require dose adjustment for both TDF and FTC, had stable
eGFR and signiﬁcant improvements in tubular function through
48 weeks after switching to once-daily E/C/F/TAF without
dose-limiting adverse events. In these patients with eGFR
,50 mL/min, adverse events were similar in grade and
frequency to patients with eGFR $50 mL/min, indicating no
untoward effects from higher FTC exposure. E/C/F/TAF was
well tolerated, and discontinuations for drug-related adverse
events were uncommon. No cases of proximal tubulopathy
occurred. Although this is a single-arm study, our data suggest
that E/C/F/TAF may be used safely in HIV-infected patients
with mild to moderate renal impairment without the need for
dose adjustment.
The improvements in renal and bone effects were
primarily experienced by patients in this study who switched
from TDF-containing regimens and likely represent a reduc-
tion in the off-target renal and bone effects of plasma TFV
concentrations, which are 90% lower with TAF. Some
prospective studies have shown that patients receiving TDF-
based therapies have signiﬁcantly greater loss of kidney
function and higher risk of acute renal failure.19 TFV
exposure has been independently associated with proteinuria,
eGFR decline, and the development eGFR ,60 mL/min in
older US veterans with elevated risk of renal disease.20 Risk
factors for TDF-related nephrotoxicity include older age,
coadministration with ritonavir-boosted protease inhibitors
(which further increase TFV plasma levels), and comorbid-
ities associated with renal disease.21
In this study, TDF-associated nephrotoxicity was as-
sessed using proteinuria (UPCR) and albuminuria (UACR)—
these tests have validated thresholds associated with elevated
risk for adverse clinical outcomes22–24 and recommended
guidelines for both HIV-infected25 and HIV-uninfected26,27
patients. Markers speciﬁc for proximal renal tubular dysfunc-
tion were also assessed (urine retinol-binding protein to
creatinine ratio and b2-microglobulin to creatinine ratio), as
recommended for monitoring TDF nephrotoxicity in current
Infectious Diseases Society of America Guidelines.25 In this
study, subjects with preexisting renal impairment who switched
from TDF-containing regimens to E/C/F/TAF had normaliza-
tion of proteinuria, albuminuria, and tubular proteinuria and
subjects who switched from non–TDF-containing regimens to
E/C/F/TAF had stable proteinuria, albuminuria, and tubular
proteinuria. Many patients had resolution of signiﬁcant pro-
teinuria and albuminuria after switching to E/C/F/TAF.
Reversal of these effects within the ﬁrst 2 weeks after switching
TABLE 3. PK Parameters of E/C/F/TAF
Mean (%CV) AUC* (ng$h/mL) Cmax (ng/mL) Ctau (ng/mL)
EVG 27,100 (32) 2390 (32) 357 (76)
COBI 9920 (45) 1290 (32) 38.3 (104)
FTC 21,000 (26) 2650 (25) 194 (34)
TAF 250 (54) 265 (69) Not applicable
TFV 552 (32) 29.3 (29) 19.2 (31)
*AUC tau was calculated for all analytes with the exception of TAF, which was
AUC last.
AUC, area under the curve; %CV, coefﬁcient of variation.
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to E/C/F/TAF suggests that TFV’s effect on kidney function, as
measured by these markers, is reversible. TFV is not a direct
inhibitor of any creatinine transporter (ie, OAT2, OCT2,
OCT3, MATE1, and MATE2K). The combined clinical results
suggest a global effect of the higher circulating levels of TFV
associated with TDF administration on proximal tubule
function. Although the exact mechanism is unknown, a recent
study has shown TFV inhibition of sodium phosphate trans-
porters that are involved in phosphate reabsorption in the
proximal tubule that may cause a perturbation in proximal
tubular ion ﬂow, consistent with this global effect.28
Treatment with TDF has consistently been associated
with less increase in lipids compared with other regimens in
treatment-naive patients. Interestingly, this study showed
increases in total and low-density lipoprotein cholesterol
and triglycerides in patients switching from TDF-containing
regimens. These changes are likely related to the signiﬁcant
reductions in plasma TFV concentrations. TDF seems to have
independent effects to lower cholesterol fractions; so, the
increases observed with switching from TDF to TAF are
consistent with the phenomenon. Of note, decreases in total,
low-density lipoprotein, and HDL cholesterol and triglycer-
ides in patients switching from non–TDF-containing regi-
mens were observed.
Strengths of this study include the clinical relevance of
the study population, which included a signiﬁcant number of
patients with moderately impaired renal function, older age,
and comorbidity, and the rigorous evaluations performed
during a full 48-week period of follow-up. Study sites were
geographically diverse. One limitation of the present study is
the single-arm noncomparative study design. However, 2
international phase 3 clinical trials comprising over 1700
patients suggested a favorable renal and bone safety proﬁle of
TAF vs TDF in a randomized double-blind design, where the
TFV prodrug was the only variable. These studies showed
that, compared with TDF, TAF-treated patients had signiﬁ-
cantly smaller reductions in eGFR, more favorable changes in
proteinuria, albuminuria, and tubular proteinuria, and more
favorable BMD.
In summary, patients with signiﬁcant comorbidities and
mild to moderate renal impairment (eGFR = 30–69 mL/min)
who switched to E/C/F/TAF had no change in estimated or
actual GFR, whereas proteinuria, proximal renal tubular
function, and BMD signiﬁcantly improved over 48 weeks.
Of particular note, patients with eGFR ,50 mL/min who
currently require dose adjustment for both TDF and FTC
had stable eGFR and signiﬁcant improvements in tubular
function through 48 weeks after switching to once-daily
E/C/F/TAF without dose adjustment. In these patients with
eGFR ,50 mL/min, adverse events were similar in grade
and frequency to patients with eGFR $50 mL/min, indicat-
ing no untoward effects from higher FTC exposure. No
cases of proximal tubulopathy occurred. E/C/F/TAF was
well tolerated and discontinuations for drug-related adverse
events were rare. Our data support the safe use of single-
tablet E/C/F/TAF in HIV+ patients with mild and moderate
renal impairment without dose adjustment over the ﬁrst year
of use. Longer duration studies are needed to conﬁrm these
initial ﬁndings.
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